Obinutuzumab for the treatment of lymphoproliferative disorders

Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving

(2014) P. V. Beum et al.   JOURNAL OF IMMUNOLOGY

Rituximab resistance

(2011) Andrew R. Rezvani et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101

(2011) M. Jak et al.   BLOOD

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

(2011) G. Niederfellner et al.   BLOOD

Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies

(2011) Anders E. Pedersen et al.   IMMUNOLOGY

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

(2011) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

(2011) S. Dalle et al.   MOLECULAR CANCER THERAPEUTICS

Rituximab-Induced Interstitial Lung Disease: Case Report and Literature Review

(2011) Aymen Zayen et al.   PHARMACOLOGY

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

The future of CD20 monoclonal antibody therapy in B-cell malignancies

(2010) Myron S. Czuczman et al.   LEUKEMIA & LYMPHOMA

Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma

(2009) Abraham Klepfish et al.   Annals of the New York Academy of Sciences

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

(2009) J. Hiraga et al.   BLOOD

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

(2009) Kenneth R Carson et al.   LANCET ONCOLOGY

Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention

(2009) Claudia Stolz et al.   LEUKEMIA & LYMPHOMA

Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma

(2009) Robert S. Boyd et al.   MOLECULAR & CELLULAR PROTEOMICS

GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment

(2008) C. Meyer zum Buschenfelde et al.   CANCER RESEARCH

Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression

(2008) S. H. Olejniczak et al.   CLINICAL CANCER RESEARCH

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

(2008) E. Racila et al.   CLINICAL CANCER RESEARCH